Phase 2 N=61 Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.
Erectile Dysfunction
Primary: Number of Participants Achieving MCID in IIEF-EF. — 14; 15; 10; 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=229 Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
Monkeypox
Primary: Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at Day 43 — 203.2; 113.2; 288.9 titer — p=0.045
Phase 2 N=43 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants
Phase 2 N=74 Guanfacine to Improve Substance Use Outcomes in Women
Substance Use Disorders
Primary: Change in Drug Use With Substance Use Calendar — -6.35; -5.61 days — p=0.08
Phase 2 N=48 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Adenocarcinoma · Pancreatic Neoplasms · Neoplasm, Glandular
Primary: Maximum Tolerated Dose (MTD) of Gemcitabine. — 500 mg/m^2
Phase 2 N=20 SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Aging
Primary: AGE-RAGE Measurement in Plasma — -172; -86 pg/mL
Phase 2 N=52 Contralaterally Controlled Functional Electrical Stimulation Plus Video Games for Hand Therapy After Stroke
Upper Extremity Hemiplegia · Stroke
Primary: Box and Block Test Score — 10.6; 11.0; 11.2; 12.4 blocks
Phase 2 N=200 Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
Hypertension, Renal
Primary: Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo — -4.10; -11.3; -11.07; -5.63 mmHg
Phase 2 N=5 A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency
Congenital Protein C Deficiency
Primary: PK Part: Protein C Activity Level of TAK-662 — 0.000; 1.746; 1.616; 1.458 international unit per milliliter(IU/ml)
Phase 2 N=42 Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
Colorectal Cancer
Primary: Efficacy Based on Progression Free Survival of Vorinostat and Hydroxychloroquine Compared to Regorafenib — 1.9; 4.35 months
Phase 2 N=90 Low Dose Continuous Furosemide Effect on Cardiac Surgery Patients With Kidney Dysfunction
Chronic Kidney Disease · Cardiac Disease
Primary: Glomerular Filtration Rate at Baseline — 56; 67 mL/mnt/1.73 m^2
Phase 2 N=43 Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Duration of Response — 98; 69 days — p=0.366
Phase 2 N=2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Mesothelioma · Peritoneal Mesothelioma
Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery
Phase 2 N=10 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
Small Cell Lung Cancer · Extra-Pulmonary Small Cell Carcinomas
Primary: Phase II: Clinical Benefit Rate
Phase 2 N=25 A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Polymyositis · Dermatomyositis
Primary: Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period — 25.5; 25.0; 33.1; 33.5 score on a scale